TY - JOUR
T1 - Hemodialysis access
T2 - Influence of the human immunodeficiency virus on patency and infection rates
AU - Curi, M. A.
AU - Pappas, P. I.
AU - Silva, Jr
AU - Patel, S.
AU - Padberg, Jr
AU - Jamil, Z.
AU - Duran, W. N.
AU - Hobson, R. W.
N1 - Funding Information:
This research was supported by grants from the National Institutes of Health (Dr Pappas, KO8 HL03354-03; and Dr Hobson, KO7 HL03437-02).
PY - 1999
Y1 - 1999
N2 - Purpose: The complication rate for patients who are dialysis dependent and infected with the human immunodeficiency virus (HIV) and the role of viral indicators (CD4 counts) as predictors of these complications are poorly characterized. To determine the influence of HIV status and vital activity on graft patency and infection rates, we retrospectively reviewed our results. Methods: Between June 1993 and March 1997, the charts of 104 patients (HIV+, n = 42; HIV-, n = 62) who required 112 hemodialysis access grafts were reviewed. Of the 112 procedures, 55 (48%) were autologous arteriovenous fistulae (AVF) procedures (HIV+, n = 23; HIV-, n = 32) and 57 (52%) were prosthetic expanded polytetrafluoroethylene grafting procedures (HIV+, n = 27; HIV-, n = 30). Transcutaneous catheter procedures were excluded from the study. The autologous AVF procedures consisted of direct and transposed AVFs. Patency rates were determined by means of life-table analysis. Infection rates and CD4 counts were compared with the χ2 test and the Fisher exact test. Significance was accepted at a P value of .05 or less. Results: The cumulative 12-month and 24-month patency rates for prosthetic grafts in patients who were HIV+ were 49% and 21%, respectively, versus 77% and 45% for patients who were HIV-. The differences in the prosthetic graft patency rates between these two groups were significant (P ≤ .05). The cumulative 12-month and 24-month patency rates for autologous AVF procedures did not differ significantly. The AVF procedure patency rates were 72% and 51%, respectively, in patients who were HIV+ versus 54% and 50% for patients who were HIV-. The prosthetic graft infection rate for patients who were HIV+ and HIV- were 30% and 7%, respectively (P = .04). However, the infection rates in autologous AVF procedures did not differ between the groups (9% vs 0%; P > .05). The mean CD4+ cell counts were 174: CD4+ counts that were less than 200 did not correlate with or predict the development of infection (P > .05). Conclusion: Our data showed that prosthetic graft infection rates were increased and patency rates were decreased in patients who were HIV+ as compared with patients who were HIV- and HIV+ with autologous AVFs. There were no differences in patency rates or infection rates in patients who had undergone autologous access procedures. Longterm graft patency rates were not affected by HIV status, and CD4+ lymphocyte counts were not predictive of infection development. Because the prosthetic graft infection rates exceeded those rates of autologous access procedures, we recommend the vigorous use of autologous AVFs in all patients who are HIV+, regardless of CD4+ count.
AB - Purpose: The complication rate for patients who are dialysis dependent and infected with the human immunodeficiency virus (HIV) and the role of viral indicators (CD4 counts) as predictors of these complications are poorly characterized. To determine the influence of HIV status and vital activity on graft patency and infection rates, we retrospectively reviewed our results. Methods: Between June 1993 and March 1997, the charts of 104 patients (HIV+, n = 42; HIV-, n = 62) who required 112 hemodialysis access grafts were reviewed. Of the 112 procedures, 55 (48%) were autologous arteriovenous fistulae (AVF) procedures (HIV+, n = 23; HIV-, n = 32) and 57 (52%) were prosthetic expanded polytetrafluoroethylene grafting procedures (HIV+, n = 27; HIV-, n = 30). Transcutaneous catheter procedures were excluded from the study. The autologous AVF procedures consisted of direct and transposed AVFs. Patency rates were determined by means of life-table analysis. Infection rates and CD4 counts were compared with the χ2 test and the Fisher exact test. Significance was accepted at a P value of .05 or less. Results: The cumulative 12-month and 24-month patency rates for prosthetic grafts in patients who were HIV+ were 49% and 21%, respectively, versus 77% and 45% for patients who were HIV-. The differences in the prosthetic graft patency rates between these two groups were significant (P ≤ .05). The cumulative 12-month and 24-month patency rates for autologous AVF procedures did not differ significantly. The AVF procedure patency rates were 72% and 51%, respectively, in patients who were HIV+ versus 54% and 50% for patients who were HIV-. The prosthetic graft infection rate for patients who were HIV+ and HIV- were 30% and 7%, respectively (P = .04). However, the infection rates in autologous AVF procedures did not differ between the groups (9% vs 0%; P > .05). The mean CD4+ cell counts were 174: CD4+ counts that were less than 200 did not correlate with or predict the development of infection (P > .05). Conclusion: Our data showed that prosthetic graft infection rates were increased and patency rates were decreased in patients who were HIV+ as compared with patients who were HIV- and HIV+ with autologous AVFs. There were no differences in patency rates or infection rates in patients who had undergone autologous access procedures. Longterm graft patency rates were not affected by HIV status, and CD4+ lymphocyte counts were not predictive of infection development. Because the prosthetic graft infection rates exceeded those rates of autologous access procedures, we recommend the vigorous use of autologous AVFs in all patients who are HIV+, regardless of CD4+ count.
UR - http://www.scopus.com/inward/record.url?scp=0032910145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032910145&partnerID=8YFLogxK
U2 - 10.1016/S0741-5214(99)70305-8
DO - 10.1016/S0741-5214(99)70305-8
M3 - Article
C2 - 10194487
AN - SCOPUS:0032910145
SN - 0741-5214
VL - 29
SP - 608
EP - 616
JO - Journal of vascular surgery
JF - Journal of vascular surgery
IS - 4
ER -